SCHEMBL30765965

SCHEMBL30765965

CC(C)(C)OC(=O)N1CCc2sc(CNC(=O)Cn3c(-c4ccccc4)ncc(NCc4ccc5oc6ccccc6c5c4)c3=O)cc2C1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.34
KMT2A Q03164 2/20 0.34
ELANE P08246 2/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
AVPR1B P47901 5/20 0.33
CASP1 P29466 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
F2 P00734 1/20 0.32
CMA1 P23946 1/20 0.32
CTRC Q99895 1/20 0.32
BACE1 P56817 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765575 0.90 AVPR1B (0.35) KMT2AAVPR1BMEN1ALDH1A1L3MBTL1
SCHEMBL30765898 0.83 ITGB3 (0.35) KMT2AELANEAVPR1BCASP1F2
SCHEMBL30765769 0.76 NTRK1 (0.40) ELANEAVPR1BCASP1F2CMA1
SCHEMBL30765838 0.75 CASP1 (0.41) ELANECASP1HDAC6CMA1CTRC
SCHEMBL30765548 0.72 F2 (0.39) KMT2AELANEAVPR1BCASP1F2
SCHEMBL30765784 0.71 NPSR1 (0.35) KMT2AELANECASP1MEN1ALDH1A1
SCHEMBL30765442 0.71 ELANE (0.38) KMT2AELANEMEN1ALDH1A1L3MBTL1
SCHEMBL30765948 0.71 LMNA (0.39) ELANECMA1CTRC
SCHEMBL23460845 0.71 F2 (0.45) P2RX3F2
SCHEMBL30765926 0.71 GAA (0.52) KMT2AELANEAVPR1BCASP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed